+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rare Autoinflammatory Diseases Drug Market - Global Forecast 2026-2032- Product Image
Rare Autoinflammatory Diseases Drug Market - Global Forecast 2026-2032- Product Image
New

Rare Autoinflammatory Diseases Drug Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 181 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6124268
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Rare Autoinflammatory Diseases Drug Market is evolving rapidly as healthcare systems, payers, and innovators respond to advances in precision immunology, improved diagnosis, and changing regulatory expectations. For senior decision-makers, understanding this shifting landscape is key to capturing value and sustaining competitive advantage.

Market Snapshot: Rare Autoinflammatory Diseases Drug Market Growth

The global rare autoinflammatory diseases drug market is projected to register notable expansion, moving from USD 3.78 billion in 2025 to USD 4.13 billion in 2026, and is anticipated to reach USD 7.23 billion by 2032, reflecting a CAGR of 9.70%. This growth trajectory is driven by earlier detection, increased clinical awareness, and continued innovation in targeted immunology therapies.

Scope & Segmentation

  • Therapy Types: Biologics, small molecules, next-generation nucleic-acid-based interventions, and gene-informed modalities.
  • Routes of Administration: Intravenous, subcutaneous, and oral formulations, with each approach affecting adherence, patient experience, and clinical practice.
  • Distribution Channels: Specialty pharmacies, hospital pharmacies, and select retail channels, highlighting variances in access, logistics, and prior authorization.
  • End Users: Hospitals, specialty clinics, and homecare settings, each presenting unique operational and training demands for chronic disease management.
  • Age Groups: Pediatric and adult populations, reflecting differences in treatment onset, dosing needs, caregiver involvement, and long-term evidence requirements.
  • Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific, each region showcasing distinct regulatory paths, reimbursement frameworks, and infrastructure for rare care delivery.

Key Takeaways for Decision-Makers

  • The market is transitioning from broad immunosuppression toward mechanism-driven, pathway-targeted therapies, demanding deeper clinical evidence and robust differentiation strategies.
  • Earlier and more precise diagnosis, supported by advanced genetic testing, is raising expectations for durable disease control while increasing the pool of eligible patients and altering longitudinal care planning.
  • Operational discipline is critical as stakeholder demands shift to measurable outcomes, including steroid-sparing effects, reduced hospitalization rates, and improved daily functioning.
  • A tight network of subspecialists and concentrated referral pathways means influence is localized, so engagement strategies must prioritize consensus-building and evidence-sharing with key clinical leaders.
  • Collaboration with patient advocacy groups, investment in registry data, and transparent communication on trial eligibility can enhance brand trust and inform meaningful patient-centered endpoints.

Tariff Impact and Supply Chain Resilience

Emerging tariff dynamics in the United States are putting supply chain, validation, and cost management under increased pressure. The direct impact often resides within supply chain layers, including active pharmaceutical ingredients, bioprocessing components, and cold-chain logistics. Companies must respond by diversifying supplier networks, qualifying secondary sources, and managing regulatory change processes to maintain reliability. Enhanced scrutiny of landed costs and logistical robustness can influence the competitive landscape in biologics and injectable therapies. Contractual clarity and operational scenario planning regarding tariffs are growing in importance as market volatility persists.

Methodology & Data Sources

We employ a triangulated methodology that blends structured secondary research with primary interviews of clinicians, payers, pharmacists, and industry experts. Analytical frameworks are applied to map clinical pathways, policy shifts, and supply exposures. Quality assurance processes standardize terminology and reconcile divergent insights to deliver actionable, credible intelligence.

Why This Report Matters

  • Enables strategic planning by clarifying how precision therapies, segmentation, and operational trends will shape future market leadership.
  • Guides investment and partnership decisions by unpacking regulatory, access, and technological factors specific to rare autoinflammatory diseases.
  • Supports confident decision-making with rigorously validated, up-to-date market intelligence across therapeutic, operational, and regional dimensions.

Conclusion

Sustained success in rare autoinflammatory diseases therapeutics now depends on aligning clinical innovation, measurable outcomes, and resilient operations. Integrating evidence generation, diagnosis-to-treatment pathways, and robust supply planning positions companies to deliver value in an environment defined by precision, credibility, and reliability.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Rare Autoinflammatory Diseases Drug Market, by Drug Class
8.1. Biologics
8.1.1. Il-1 Inhibitors
8.1.2. Il-6 Inhibitors
8.1.3. Tnf Inhibitors
8.2. Corticosteroids
8.3. Small Molecule Inhibitors
9. Rare Autoinflammatory Diseases Drug Market, by Route Of Administration
9.1. Intravenous
9.2. Oral
9.3. Subcutaneous
10. Rare Autoinflammatory Diseases Drug Market, by Indication
10.1. Cryopyrin-Associated Periodic Syndromes
10.1.1. Familial Cold Autoinflammatory Syndrome
10.1.2. Muckle-Wells Syndrome
10.1.3. Neonatal-Onset Multisystem Inflammatory Disease
10.2. Familial Mediterranean Fever
10.3. Hyperimmunoglobulin D Syndrome
10.4. Tumor Necrosis Factor Receptor Associated Periodic Syndrome
11. Rare Autoinflammatory Diseases Drug Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Rare Autoinflammatory Diseases Drug Market, by End User
12.1. Adult Patients
12.2. Geriatric Patients
12.3. Pediatric Patients
13. Rare Autoinflammatory Diseases Drug Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Rare Autoinflammatory Diseases Drug Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Rare Autoinflammatory Diseases Drug Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Rare Autoinflammatory Diseases Drug Market
17. China Rare Autoinflammatory Diseases Drug Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AB2 Bio Ltd
18.6. ACELYRIN, Inc.
18.7. Aslan Pharmaceuticals Limited
18.8. BioCryst Pharmaceuticals, Inc.
18.9. CSL Behring GmbH
18.10. Humanigen, Inc.
18.11. Immedica Pharma AB
18.12. Inmagene Biopharmaceuticals
18.13. Janssen Biotech, Inc.
18.14. Kiniksa Pharmaceuticals, Ltd.
18.15. Mabpharm Limited
18.16. Novartis AG
18.17. Pharming Group N.V.
18.18. Regeneron Pharmaceuticals, Inc.
18.19. RPharm
18.20. Swedish Orphan Biovitrum AB
18.21. Takeda Pharmaceutical Company Limited
18.22. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-6 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-6 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL COLD AUTOINFLAMMATORY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL COLD AUTOINFLAMMATORY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL COLD AUTOINFLAMMATORY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MUCKLE-WELLS SYNDROME, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MUCKLE-WELLS SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MUCKLE-WELLS SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY NEONATAL-ONSET MULTISYSTEM INFLAMMATORY DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY NEONATAL-ONSET MULTISYSTEM INFLAMMATORY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY NEONATAL-ONSET MULTISYSTEM INFLAMMATORY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL MEDITERRANEAN FEVER, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL MEDITERRANEAN FEVER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL MEDITERRANEAN FEVER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HYPERIMMUNOGLOBULIN D SYNDROME, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HYPERIMMUNOGLOBULIN D SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HYPERIMMUNOGLOBULIN D SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 108. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 110. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 111. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 112. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 113. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 114. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 115. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 126. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 127. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 129. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 130. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 143. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 144. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 145. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 146. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 147. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 148. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 151. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 152. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 153. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 154. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 155. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 167. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 168. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 169. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 170. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 171. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 172. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 173. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 174. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 175. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 176. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 177. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 178. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 179. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 181. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 182. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 183. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 184. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 185. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 186. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 187. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 188. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 189. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 191. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 192. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 193. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 194. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 195. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 196. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 197. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 198. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 199. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 200. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 201. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 202. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 203. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
TABLE 204. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 205. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Rare Autoinflammatory Diseases Drug market report include:
  • AB2 Bio Ltd
  • ACELYRIN, Inc.
  • Aslan Pharmaceuticals Limited
  • BioCryst Pharmaceuticals, Inc.
  • CSL Behring GmbH
  • Humanigen, Inc.
  • Immedica Pharma AB
  • Inmagene Biopharmaceuticals
  • Janssen Biotech, Inc.
  • Kiniksa Pharmaceuticals, Ltd.
  • Mabpharm Limited
  • Novartis AG
  • Pharming Group N.V.
  • Regeneron Pharmaceuticals, Inc.
  • RPharm
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages181
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 4.13 Billion
Forecasted Market Value ( USD ) by 2032 $ 7.23 Billion
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

Rare Diseases Treatment Market - Global Forecast 2025-2032 - Product Image

Rare Diseases Treatment Market - Global Forecast 2025-2032

  • Report
  • 196 Pages
  • Global
From
Zollinger Ellison Syndrome Market Report and Forecast 2025-2034 - Product Image

Zollinger Ellison Syndrome Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Rare Disease Treatment Market Outlook 2037 - Product Image

Rare Disease Treatment Market Outlook 2037

  • Report
  • 274 Pages
  • Global
From
Rare Diseases Treatment Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Rare Diseases Treatment Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Rare Diseases Treatment Market Report 2025 - Product Image

Rare Diseases Treatment Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.